TD Cowen lowered the firm’s price target on Ginkgo Bioworks to $3 from $7 and keeps an Outperform rating on the shares. The firm said they posted a weaker Q4 and 2024 Guidance on revenue and programs underwhelmed but should find key drivers in biopharma and government adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DNA:
- Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results
- Ginkgo Bioworks acquires Proof Diagnostics, no terms disclosed
- Ginkgo Bioworks acquires Patch Biosciences, no terms disclosed
- Ginkgo Bioworks acquires key assets of Reverie Labs, no terms
- Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers
